Literature DB >> 7780152

Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings.

A Cuneo1, A Ferrant, J L Michaux, M Boogaerts, H Demuynck, A Van Orshoven, A Criel, M Stul, P Dal Cin, J Hernandez.   

Abstract

Cytogenetic data were studied in 26 patients with de novo acute myeloid leukemia (AML) with minimal myeloid differentiation, corresponding to the M0 subtype of the French-American-British classification, in correlation with cytoimmunologic and clinical findings. Clonal abnormalities were detected in 21 cases (80.7%), 12 of which had a complex karyotype. Partial or total monosomy 5q and/or 7q was found, either as the sole aberration or in all abnormal metaphases, in 11 patients; in 8 cases, additional chromosome changes were present, including rearrangements involving 12p12-13 and 2p12-15 seen in 3 cases each. Five patients had trisomy 13 as a possible primary chromosome change; in 5 cases, nonrecurrent chromsome abnormalities were observed. Comparison of these findings with chromosome data from 42 patients with AML-M1 shows that abnormal karyotypes, complex karyotypes, unbalanced chromosome changes (-5/5q- and/or -7/7q- and +13) were observed much more frequently in AML-M0 than in AML-M1. Patients with abnormalities of chromosome 5 and/or 7 frequently showed trilineage myelodysplasia and low white blood cell count. Despite their relatively young age, complete remission was achieved in 4 of 11 patients only. Patients with +13 were elderly males with frequent professional exposure to myelotoxic agents. Unlike patients with clonal abnormalities, most AML-M0 patients with normal karyotype showed 1% to 2% peroxidase-positive blast cells at light microscopy and frequently achieved CR. It is concluded that (1) AML-M0 shows a distinct cytogenetic profile, partially recalling that of therapy-related AML, (2) different cytogenetic groups of AML-M0 can be identified showing characteristic clinicobiologic features, and (3) chromosome rearrangements may partially account for the unfavorable outcome frequently observed in these patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7780152

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Acute Myeloid Leukaemia : AML M0 with 11q deletion.

Authors:  T Chatterjee; G S Chowdhary; R Singh; V Srinivas; S Bandyopadhyay; V K Kataria; K P Anand
Journal:  Med J Armed Forces India       Date:  2011-07-21

2.  TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation.

Authors:  Keyur P Patel; Faisal A Khokhar; Tariq Muzzafar; M James You; Carlos E Bueso-Ramos; Farhad Ravandi; Sherrie Pierce; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2012-08-31       Impact factor: 7.842

3.  Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961.

Authors:  Draga Barbaric; Todd A Alonzo; Robert B Gerbing; Soheil Meshinchi; Nyla A Heerema; Dorothy R Barnard; Beverly J Lange; William G Woods; Robert J Arceci; Franklin O Smith
Journal:  Blood       Date:  2006-12-07       Impact factor: 22.113

4.  Two independent clones in myelodysplastic syndrome following treatment of acute myeloid leukemia.

Authors:  Masahiro Masuya; Naoyuki Katayama; Koichi Inagaki; Hiroshi Miwa; Natsuki Hoshino; Hiroyuki Miyashita; Hirohito Suzuki; Hiroto Araki; Hidetsugu Mitani; Kazuhiro Nishii; Shin-ichi Kageyama; Nobuyuki Minami; Hiroshi Shiku
Journal:  Int J Hematol       Date:  2002-02       Impact factor: 2.490

5.  Genome wide molecular analysis of minimally differentiated acute myeloid leukemia.

Authors:  Fernando P G Silva; Inês Almeida; Bruno Morolli; Geeske Brouwer-Mandema; Hans Wessels; Rolf Vossen; Harry Vrieling; Erik W A Marijt; Peter J M Valk; Hanneke C Kluin-Nelemans; Wolfgang R Sperr; Wolf-Dieter Ludwig; Micheline Giphart-Gassler
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

6.  Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0.

Authors:  Ritsuro Suzuki; Makoto Murata; Masahiro Kami; Shigeki Ohtake; Norio Asou; Yoshihisa Kodera; Masao Tomonaga; Yasufumi Masaki; Shuya Kusumoto; Jin Takeuchi; Shin Matsuda; Hisamaru Hirai; m Seiichi Yorimitsu; Nobuyuki Hamajima; Masao Seto; Masanori Shimoyama; Ryuzo Ohno; Yasuo Morishima; Shigeo Nakamura
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

7.  Establishment of an undifferentiated leukemia cell line (Kasumi-3) with t(3;7)(q27;q22) and activation of the EVI1 gene.

Authors:  H Asou; K Suzukawa; K Kita; K Nakase; H Ueda; K Morishita; N Kamada
Journal:  Jpn J Cancer Res       Date:  1996-03

8.  CD105 (Endoglin) as negative prognostic factor in AML.

Authors:  Joseph Kauer; Karolin Schwartz; Claudia Tandler; Clemens Hinterleitner; Malte Roerden; Gundram Jung; Helmut R Salih; Jonas S Heitmann; Melanie Märklin
Journal:  Sci Rep       Date:  2019-12-04       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.